Pfizer’s RSV Vaccine Wins US Panel’s Backing for Safety in Older People

Pfizer’s RSV Vaccine Wins US Panel’s Backing for Safety in Older People
- Narrow votes reflect advisory panel’s concerns about data
- Postmarketing studies will be crucial, panel members sayhttps://t.co/rnIjgf8BMw

— Wittgenstein (@backtolife_2023) February 28, 2023